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A B S T R A C T
We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the
Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and
risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for 2 years after ﬁrst HCT
without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of
LFIs was 6.4% (95% conﬁdence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in
pediatric subjects; P < .001). In adults, the 2 most signiﬁcant risks for developing LFI were increasing age (20 to
39, 40 to 54, and 55 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86
(95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD
(cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR,
3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most signiﬁcant risks for developing LFI were a history of
cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited
abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI,
1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued
vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD.
© 2018 American Society for Blood and Marrow Transplantation.

INTRODUCTION
Late fatal infections (LFIs) occurring 2 years after HCT
remain a signiﬁcant contributing factor to mortality post-HCT [1].
However, data are limited on the incidence of LFI, the types of
infections responsible for death, and recipient-, disease-, and
HCT-related risk factors associated with LFI in adult and pediatric
patients surviving for 2 years after HCT. Previous studies
addressing LFI after HCT were limited by small sample size,
response bias, inadequate follow-up, and incomplete data reporting from transplantation centers. To address this knowledge gap,
we performed a detailed analysis of LFI in HCT recipients
reported to the Center for International Blood and Marrow Transplant Research (CIBMTR), including the incidence, types of infections, and risk factors.
METHODS
Data Source
The CIBMTR includes a network of more than 450 transplantation centers
worldwide that contribute data on consecutive transplantations performed
at each center to a centralized registry. All patients are followed longitudinally until lost to follow-up or death. The quality of the data reported by all
participating centers is monitored by computerized error checks, physician
data review, and periodic onsite patient record audits.
Study Design
The study population consisted of subjects with hematologic malignancies and nonmalignant conditions who underwent HCT between January 1,
1995, and December 31, 2011. To minimize selective reporting bias, patients
were selected only from centers with a team follow-up completeness index
80% at 4 years (n = 344 centers and n = 43,345 patients). The completeness
index is deﬁned as the ratio of total observed person-time to the potential
person-time of follow-up [2]. Subjects who received stem cells grafts from
syngeneic donors or multiple donors (n = 583) were excluded. Approximately
57% (n = 24,420) of the patients were then excluded for death or relapse
within 24 months of HCT. Subjects missing baseline, 100-day, or disease-speciﬁc forms (n = 193) and without available consent (n = 638) were excluded.

Subjects with severe combined immunodeﬁciency and other immune system
disorders associated with incomplete immune reconstitution after HCT
(n = 1017) were excluded from the analysis. Subjects with nonmyeloma
plasma cell disorders (n = 7) were also excluded owing to low numbers. Previous autologous HCT (n = 759) was permitted for study inclusion. Subjects who
were lost to follow-up (n = 549) and subjects with missing survival data
(n = 19) or cause of death data (n = 495) were excluded from the analysis. A
total of 15,424 patients were included in the ﬁnal study population, with
10,336 adult and 5,088 pediatric patients.

Statistical Analysis
Pediatric patients age 0 to 17 years and adult patients age 18 to 79 years
were analyzed separately because of differences in disease biology, pretransplantation treatment, graft source, conditioning regimen, overall post-transplantation mortality, and causes of post-transplantation mortality. Relapse or
second HCT at 2 years after the initial HCT was reported in 1263 adult
patients (12%) and in 297 pediatric patients (6%), who were censored at the
event. In a multivariate analysis of the pediatric population, 1 patients with
multiple myeloma age <18 years and 64 patients missing data on graft-versus-host disease (GVHD) were excluded.
Potential risk factors for late death from infection included age at HCT,
sex, race, geographic region of the center, Karnofsky or Lansky Performance
Score at HCT, disease, previous autologous HCT, CIBMTR disease risk index,
time from diagnosis to HCT, human immunodeﬁciency virus (HIV) status,
donor type, HLA match, stem cell source, donor/recipient cytomegalovirus
(CMV) status, conditioning regimen, dose of total body irradiation (TBI),
GVHD prophylaxis regimen, use of T cell depletion, year of HCT, presence of
fungal infections before HCT, and development of acute GVHD (aGVHD) and
chronic GVHD (cGVHD) within the ﬁrst 2 years after HCT. The effect of these
covariates on mortality due to infection was analyzed by marginal Cox
regression models, which allow for adjustment for clustering within centers.
All potential risk factors were checked with time-dependent covariates to
ensure that assumptions of proportionality were met. Backward elimination
procedures were used to identify signiﬁcant variables to include in the ﬁnal
model. Interactions between donor source and GVHD status at 2 years, as well
as conditioning and GVHD status at 2 years, were evaluated in the regression
models for adult population. A similar assessment was not possible for the pediatric population owing to the low number of events in this cohort. A
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signiﬁcance level of a = .05 was used. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

months) in the adult patients and 100 months (range, 24 to
247 months) in the pediatric patients.

RESULTS
Patient Characteristics
The ﬁnal study population included 10,336 adult patients
from 267 transplantation centers and 5088 pediatric patients
from 202 centers. Patient, disease, and transplantation characteristics are shown in Table 1. The median age at HCT was 44
years (range, 18 to 79 years) years in the adult patients and 9
years (range, <1 to 17 years) in the pediatric patients. The
median follow-up intervals were 97 months (range, 24 to 251

Pretransplantation Infections, Graft Sources, and GVHD
Among 10,336 adult subjects, 884 (9%) had a clinically signiﬁcant fungal infection before HCT, and 318 (3%) were
HIV-seropositive. Graft sources included bone marrow (BM) in
3479 patients (34%), granulocyte-colony stimulating factormobilized peripheral blood stem cells in 6347 (61%), and cord
blood in 510 (5%). Myeloablative conditioning was used in
6807 patients (66%), and reduced-intensity/nonmyeloablative
conditioning was used in 3339 patients (32%). A history of
aGVHD, limited, or extensive cGVHD by 2 years post-HCT was
reported in 3559 (34%), 1315 (13%), and 4912 (48%) patients,
respectively.
Among 5088 evaluable pediatric subjects, 418 (8%) had a
clinically signiﬁcant fungal infection before HCT, and 75 (1.5%)
were HIV seropositive. Graft sources included BM in 3395
(67%), granulocyte-colony stimulating factor-mobilized
peripheral blood stem cells in553 (11%), and cord blood in
1140 (22%). Myeloablative conditioning was used in 4064
patients (80%), and reduced-intensity/nonmyeloablative conditioning was used in 997 (19%). A history of aGVHD, limited
cGVHD, and extensive cGVHD within 2 years of HCT was
reported in 1522 (30%), 109 (2%), and 858 (17%) patients,
respectively.

Table 1
Characteristics of the Study Population: HCT Recipients Who Were DiseaseFree at Least 24 Months after Transplantation
Variable

Population
Adult
(18 yr)

Number of patients
Number of centers
Patient age at HCT, yr, median (range)
Sex, n (%)
Male
Female
Performance score, n (%)
90
<90
Missing
Disease, n (%)
AML
Acute lymphoblastic leukemia
Other leukemia
Myelodysplastic syndrome
Other myeloproliferative neoplasms
Non- Hodgkin lymphoma
Hodgkin lymphoma
Multiple myeloma
SAA
Inherited abnormalities of
erythrocyte diff/function
Interval from diagnosis to
transplantation, mo, median (range)
Conditioning regimen, n (%)
Myeloablative
Reduced intensity/nonmyeloablative
Missing
Graft source, n (%)
BM
Peripheral blood
Cord blood
Donor type, n (%)
HLA-identical sibling
Other relative
HLA-matched unrelated donor
HLA-mismatched unrelated donor
Unrelated donor missing HLA data
Cord blood
History of aGVHD (at 2 yr post-HCT), n (%)
No
Yes
Missing
Composite history of GVHD (before 2-yr
starting point), n (%)
No GVHD
Acute only
cGVHD, on immunosuppression at 2 yr
cGVHD, off immunosuppression at 2 yr
cGVHD, unknown immunosuppression
status at 2 years
Missing all GVHD data
Follow-up of survivors,
mo, median (range)

Pediatric
(<18 yr)

10,336
267
44 (18-79)

5088
202
9 (<1-17)

5888 (57)
4448 (43)

2898 (57)
2190 (43)

7124 (69)
2689 (26)
523 (5)

4148 (82)
750 (15)
190 (4)

4134 (40)
1363 (13)
574 (6)
865 (8)
701 (7)
1335 (13)
173 (2)
237 (2)
821 (8)
133 (1)

1162 (23)
1607 (32)
98 (2)
182 (4)
252 (5)
94 (2)
13 (<1)
1 (<1)
826 (16)
853 (17)

9 (<1-540)

10 (<1-210)

6807 (66)
3339 (32)
190 (2)

4064 (80)
977 (19)
47 (1)

3479 (34)
6347 (61)
510 (5)

3395 (67)
553 (11)
1140 (22)

4509 (44)
290 (3)
3774 (37)
984 (10)
269 (3)
510 (5)

2003 (39)
249 (5)
1042 (21)
422 (8)
232 (5)
1140 (22)

6668 (65)
3559 (34)
109 (1)

3509 (69)
1522 (30)
57 (1)

3054 (30)
932 (9)
3325 (32)
1415 (14)
1506 (15)

2755 (54)
696 (14)
563 (11)
566 (11)
444 (9)

104 (1)
97 (24-251)

64 (1)
100 (24-247)

LFI in the Context of Other Causes of Death
In the study population, 2245 adult patients (22%) died
from various causes, including 839 patients (37%) who had a
post-HCT relapse or underwent a second HCT. These latter
patients were censored at that date. In the remaining 1406
patients, the leading primary causes of death were cGVHD
(n = 340; 24%), organ failure (n = 335; 24%), and infection
(n = 311; 22%). Infection was reported as a contributing cause
of death in 185 patients (13%). A total of 377 pediatric patients
(7%) died from various causes, including 151 patients (40%)
who had a post-HCT relapse or a second HCT and were censored at that date. Among the remaining 226 patients, the
leading causes of death were organ failure (n = 48; 21%), subsequent malignancy (n = 44; 19%), and GVHD (n = 43; 19%). Infection was reported as a primary cause of death in 41 patients
(18%) and as a contributory cause of death in 27 (12%).
Types of Infections at 2 Years Post-HCT
Types of infection as causes of death in the adult and pediatric patients are listed in Table 2. Bacterial infections were the
most common primary or contributing causes of LFI after HCT
in both age groups. A substantial proportion of patients in both
groups had unspeciﬁed infections or infections without a
deﬁnitive reported pathogen.
The Risk of LFI at 2 Years Post-HCT
There was a continuous increase in the risk of LFI over time
beyond 2 years post-HCT. As shown in Figure 1, in adults there
was a progressive rise in the cumulative incidence of LFI after
2 years, from 1.8% at 3 years (95% conﬁdence interval [CI],
1.5% to 2.0%) to 5.3% (95% CI, 4.9% to 5.8%) at 8 years and 6.4%
(95% CI, 5.8% to 7.0%) at 12 years. In contrast, in children, the
increase in LFI over time was signiﬁcantly smaller, .4% (95% CI,
.3% to .6%) at 3 years, 1.3% (95% CI, 1.0% to 1.7%) at 8 years, and
1.8% (95% CI, 1.4% to 2.3%) at 12 years (P < .001).
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Risk Factors for Infectious Death
In adult patients age 20 years, male sex and receipt of a
matched unrelated donor (MUD) or mismatched unrelated
donor (MMUD) HCT were independently associated with an
increased risk of LFI in multivariate analysis (Table 3). Older
age cohorts were associated with incrementally higher LFI
rates (Table 3). Patients with a history of cGVHD with ongoing
immunosuppression at 2 years post-HCT had a signiﬁcantly
increased risk of LFI (hazard ratio [HR], 3.87; P < .0001) and a
higher cumulative incidence of LFI (P < .0001) compared with
patients without any reported GVHD (Table 3 and Figure 2A).
In contrast, there was no statistically signiﬁcant increased risk
of LFI in patients with aGVHD (HR, 1.09; P = .7310) or in
patients with a history of cGVHD without ongoing immunosuppression by 2 years post-HCT (HR, 1.25; P = .3610) (Table 3).
Other factors, including primary disease, Karnofsky Performance Score, race and ethnicity, disease diagnosis, previous
autologous HCT, preexisting fungal infection, HIV seropositivity, CIBMTR Disease Risk Index, time from diagnosis to HCT,
conditioning regimen intensity, use of TBI, graft source, use of
ATG or alemtuzumab before HCT, donor/recipient CMV serostatus, geographic region, and year of HCT, were not signiﬁcantly associated with an increased risk for LFI.
In pediatric subjects age 10 years, receipt of MUD or
MMUD HCT and inherited abnormalities of erythrocyte function (AEF) were independently associated with an increased
risk of LFI (Table 4). In contrast, severe aplastic anemia (SAA)
was associated with a decreased risk of LFI in multivariate
analysis. Compared with patients without any reported GVHD,
a history of cGVHD with ongoing immunosuppression at
2 years post-HCT (HR, 9.49; P < .0001) and a history of cGVHD
without ongoing immunosuppression by 2 years post-HCT
(HR, 2.79; P = .0395), but not history of aGVHD (HR, 2.07;
P = .16), were signiﬁcantly associated with a signiﬁcantly
increased risk of LFI (Table 4) and a higher cumulative incidence of LFI (P < .001) (Figure 2B). Karnofsky/Lansky Performance Score, race and ethnicity, sex, previous autologous HCT,
preexisting fungal infections, HIV seropositivity, CIBMTR Disease Risk Index, time from diagnosis to HCT, conditioning regimen intensity, graft source, use of TBI, use of ATG or
alemtuzumab before HCT, donor/recipient CMV serostatus,

Figure 1. Cumulative incidence of death from infection after 2 years of survival in adult and pediatric patients. *Death from another cause was considered a competing risk, and patients were censored at relapse or second
transplantation.

geographic region, and year of HCT were factors that did not
increase the risk of LFI.

Identiﬁed Pathogens Causing Death
In 195 adult patients, an identiﬁed pathogen was listed as a
primary cause of death, including bacterial infections in 108
(55%), viral infections in 29 (16%), fungal infections in 35 (18%),
and multiple infections in 22 (11%). These infections included
vaccine-preventable infections in 13 patients (7%; Streptococcus
pneumoniae, inﬂuenza, hepatitis B) and drug-preventable infection in 1 patient (.5%; Pneumocystis jirovecii pneumonia). In the
pediatric cohort, pathogens as a primary cause of death were
identiﬁed in 21 patients, including bacterial infections in 13
(62%), fungal infections in 7 (33%), and multiple infections in 1
(5%). These included vaccine-preventable infections in 2
patients (10%; S. pneumoniae) and drug-preventable infections
in 3 patients (15%; Candida species, P. jirovecii pneumonia).
Table 3
Multivariate Analysis of Factors Associated with LFIs in the Adult Population
(N = 10,336)
Variable

Table 2
Types of LFI in HCT Recipients Who Were Disease-Free for at Least 24 Months
after Transplantation
Parameter

Patients who died from infection, n*
Infection listed as the primary cause of death, n (%)
Bacterial
Viral
Fungal
Protozoal
Unspeciﬁed
Multiple types reported
Infection listed as contributing cause of death, n (%)
Bacterial
Viral
Fungal
Protozoal
Unspeciﬁed
Multiple types reported

Value
Adult

Pediatric

496
311
108 (35)
29 (9)
35 (11)
1 (<1)
116 (37)
22 (7)
185
85 (46)
29 (16)
20 (11)
0
49 (26)
2 (1)

68
41
13 (32)
0
7 (17)
0
20 (49)
1 (2)
27
10 (37)
5 (18)
4 (15)
0
8 (30)
0

* Patients with relapse or second HCT occurring 2 years after HCT were
censored at the event and excluded from this analysis.

365

Age, yr
18-19
20-39
40-54
55+
Sex
Male
Female
Donor
Matched sibling
Other relative
Matched unrelated
Mismatched unrelated
Unrelated, match unknown
Cord blood
History of GVHD within 2 yr of HCT
None
aGVHD only
cGVHD,
immunosuppression at 2 yr
cGVHD, off
immunosuppression by 2 yr
cGVHD, unknown
immunosuppression at 2 yr
Missing
* Overall P value.

Number

HR (95% CI)

P Value

498
3849
3730
2259

1.00
<.0001*
3.12 (1.33-7.32)
.0089
3.86 (1.66-8.95)
.0017
5.49 (2.32-12.99)
.0001

5888
4448

1.00
.79 (.65-.96)

4509
290
3774
984
269
510

1.00
1.04 (.56-1.92)
1.65 (1.34-2.05)
1.88 (1.35-2.62)
1.60 (.99-2.59)
.80 (.37-1.74)

<.0001*
.9067
<.0001
.0002
.0563
.5778

3052
932
3325

1.00
1.09 (.67-1.76)
3.87 (2.59-5.78)

<.0001*
.7310
<.0001

1415

1.25 (.77-2.02)

.3610

1506

4.14 (2.82-6.09)

<.0001

106

4.90 (2.61-9.17)

<.0001

.0168

366
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Table 4
Multivariate Analysis of Factors Associated with LFIs in the Pediatric Population (N = 5053)
Variable
Age, yr
0-9
10-17
Donor
Matched sibling
Other relative
Matched unrelated
Mismatched unrelated
Unrelated, match unknown
Cord blood
History of GVHD within 2 years of HCT
None
aGVHD only
cGVHD,
immunosuppression. at 2 yr
cGVHD, off
immunosuppression by 2 yr
cGVHD, unknown
immunosuppression at 2 yr
Disease
AML
Acute lymphoblastic leukemia
Other leukemia
Myelodysplastic syndrome
Other myeloproliferative neoplasms
Lymphoma
SAA
AEF

Number

HR (95% CI)

P Value

2885
2138

1.00
1. 92 (1.15-3.2)

.0122

1980
246
1025
418
231
1123

1.00
1.24 (.41-3.73)
1.98 (1.02-3.86)
3.51 (1.73-7.08)
1.60 (.57-4.46)
1.38 (.70-2.75)

.0216*
.6986
.0440
.0005
.3711
.3554

2755
696
562

1.00
<.0001*
2.07 (.75-5.72)
.1600
9.49 (4.39-20.51) <.0001

566

2.79 (1.05-7.43)

444

9.68 (4.38-20.51) <.0001

1146
1588
96
179
247
104
817
846

1.00
.85 (.47-1.52)
1.56 (.38-6.46)
.62 (.14-2.71)
.88 (.30-2.55)
1.11 (.24-5.02)
.22 (.05-.94)
2.30 (1.19-4.42)

.0395

.0027*
.5719
.5428
.5222
.8064
.8965
.0409
.0129

* Overall P value.

Figure 2. (A) Cumulative incidence of LFI in adults based on history of GVHD.
(B) Cumulative incidence of LFI in pediatric patients based on history of GVHD.
*Death from another cause was considered a competing risk, and patients
were censored at relapse or second transplantation.

DISCUSSION
In this study, we performed an analysis of LFI in the largest
group of HCT survivors with long-term follow-up reported to
date. Because disease relapse and relapse-directed interventions
signiﬁcantly increase the risk of severe infections, we censored
patients with relapse or second HCT occurring after 2 years after
initial HCT to analyze the impact of other less well-known factors
on LFI in long-term survivors. This is the ﬁrst analysis to analyze
LFI separately in adult and pediatric patients and to estimate the
impact of both GVHD and immunosuppression on LFI.
Although the cumulative incidence of LFI was low in HCT
recipients, it contributed to one-third of all deaths occurring at
least 2 years after HCT in both pediatric and adult patients.
Older age, HCT from unrelated donors, male sex, and history of
cGVHD with ongoing immunosuppression at 2 years post-HCT
were associated with an increased risk of LFI in adult patients.
This is the ﬁrst comprehensive analysis of LFI in a large cohort
of pediatric patients. Despite differences in primary diseases,
intensity of conditioning regimens, graft sources, and lower
incidence and severity of cGVHD and late mortality rate compared with adult patients, LFI contributed to one-third of all
deaths at 2 years post-HCT in pediatric patients, similar to
adult patients. Age 10 years, history of cGVHD either with or
without ongoing immunosuppression at 2 years post-HCT, and
AEF were associated with an increased risk of LFI in pediatric
patients. A signiﬁcantly reduced risk of LFI in pediatric patients
with SAA requires further studies; it may be speculated that
patients with SAA predominantly receive BM transplants from

sibling donors, which is associated with a lower risk of cGVHD
compared with other donor sources [3]. In our study, pediatric
patients with SAA had a signiﬁcantly lower incidence of
cGVHD at 2 years post-HCT compared with patients with acute
myelogenous leukemia (AML) (22% versus 34%; P < .0001).
Several previous studies have demonstrated that long-lasting impairment of the immune system can lead to increased
risk of late infections after HCT [4-6]. Older age at HCT is associated with impaired recovery of CD4+ T cells following HCT,
leading to an increased risk of opportunistic infections [7] and
a decreased response to vaccination [8]. One of the ﬁrst published analyses of late infection after HCT included 89 patients
with aplastic anemia and acute leukemia who survived for 6
months after allogeneic or syngeneic HCT [9]. In that study,
conducted decades ago, bacterial infections of the respiratory
tract and skin and bacteremia represented more than one-half
of all reported infections, and 9% of affected patients died from
infectious complications. cGVHD was the sole variable signiﬁcantly associated with increased risk for late infections [9]. The
incidence of and risk factors for late infections were retrospectively evaluated in a larger study that included 196 recipients
with aplastic anemia, chronic myelogenous leukemia, and AML
who underwent HCT from matched related donors, with a
median follow-up of 8 years [10]. Late severe bacterial infections were the most frequent infections, with an 8-year cumulative incidence of 15%, and the development of extensive
cGVHD was identiﬁed as a risk factor for the development of
these infections [10]. A large single-center retrospective study
focused on long-term survival of 389 HCT recipients surviving
disease-free at 1 year after HCT identiﬁed late infections,
cGVHD, and relapsed disease as the top 3 causes of mortality
beyond the ﬁrst year post-HCT [11]. Patients with cGVHD
requiring immunosuppression at 1 year after HCT had signiﬁcantly higher mortality compared with those not on immunosuppression; however, the role of infections in patients who
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died from cGVHD is not reported in this study [11]. Even in
long-term survivors surviving for 5 years after HCT, life
expectancy continues to be lower than expected due to
increased nonrelapse mortality, including infections, which
were the third most common cause of mortality and constituted 12% of all deaths [12].
In a large single-center study including 429 HCT recipients
who received myeloablative conditioning and who were alive
and free of their original disease for 2 years post-HCT, 16%
patients developed recurrent respiratory tract infections, 1%
had recurrent urinary tract infections, and only 1 patient
developed pulmonary aspergillosis [13]. The largest study
reported to date focusing on late complications of HCT
included 10,632 patients who were alive and disease-free at
2 years after receiving myeloablative conditioning HCT for
AML, acute lymphoblastic leukemia, myelodysplastic syndrome, and lymphoma [1]. In that study, the rate of late death
remained higher than expected for each disease compared
with an age-, sex-, and nationality-matched general population. Deaths due to infection, which included only those
infections occurring without active GVHD or ongoing GVHD
therapy, varied from 4% to 17% of all deaths depending on disease diagnosis at the time of HCT and the duration of post-HCT
follow-up. In our study, the risk of LFI was not higher in cord
blood graft recipients compared with sibling donor graft recipients, but it was higher in unrelated donor transplant recipients. We hypothesize that the increased risk of LFI in unrelated
donor transplants, but not in cord blood transplants in both
pediatric and adult recipients, is associated with increased
incidence and or severity of cGVHD in these patients.
In the present study, an increased risk of LFI in long-term
survivors after HCT was associated with older age and history
of cGVHD, which adversely impact immune reconstitution for
many years after HCT. Despite the introduction of novel antimicrobial therapies to the clinic and the development of supportive care guidelines, the year of HCT had no signiﬁcant
impact on the risk of LFI in our study. Therefore, a stronger
emphasis on post-HCT vaccinations, avoidance of infectious
exposures, and increased awareness of primary providers of
the possibility of LFI and infection control should be advocated
in long-term survivors after HCT. HCT survivors themselves
should be educated about increased risk of LFI and instructed
to promptly alert healthcare provides if they develop symptoms suggestive of LFI. We showed that pediatric patients with
inherited AEF had an increased risk of LFI. In our study, 21% of
these patients had sickle cell disease (SCD). Previously, Gluckman et al. reported similar observation of increased fatal infections in patients with SCD post-HCT [14]. Although data on
previous splenectomy or functional hyposplenism were not
available for these patients, an increased risk of LFI suggests an
increased importance of prolonged antimicrobial prophylaxis
and vaccination in this group of patients. Vaccine- and drugpreventable LFI were low in our study, which may suggest that
majority of transplantation centers included in our study were
following protocols for post-HCT vaccinations and antimicrobial prophylaxis.
Our study has several limitations. Despite our strong
emphasis on the completeness of data reporting, some important information was not available for analysis. Although the
study was adjusted for center effect, several data elements
related to center practices, such as vaccination schedules, use
of antimicrobials for prophylaxis, and therapy for LFI were not
collected and were not evaluated in this study. Although most
reports noted the category of infection (bacterial, viral, fungal),
the majority of speciﬁc causative pathogens were not captured
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in the reporting forms. Rates of preventable infections are
underestimated in the present analysis owing to the large
number of unspeciﬁed infections for both adult and pediatric
subjects. Detailed information is lacking on the activity of
cGVHD and therapy with systemic immunosuppression at the
time of development of LFI.
In conclusion, this study demonstrates that in both adult
and pediatric HCT recipients surviving for 2 years post-HCT LFI
contributed to one-third of all deaths. This emphasizes the
importance of continued long-term monitoring for infections,
and the education of primary health care teams to decrease
risk of LFI in long-term HCT recipients. Future studies should
examine data on immune reconstitution, immunoglobulin levels, vaccinations, and postvaccination titers.
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